论文部分内容阅读
卵巢癌一直高居妇科恶性肿瘤病死率之首。卵巢癌细胞化疗耐药成为其临床治疗效果欠佳、病死率增加的根本性原因,因此寻找卵巢癌铂类药物耐药相关的机制对于提高卵巢癌化疗疗效至关重要。核干细胞因子(Nucleostemin)的病理生理作用主要涉及细胞的增殖及凋亡等方面。Nucleostemin信使RNA以及Nucleostemin蛋白在卵巢癌实体瘤中特异性高表达,并且与病理分级呈正相关。因此,深入研究Nucleostemin与卵巢癌化疗敏感性及分子机制十分关键。
Ovarian cancer has always been the highest mortality of gynecological malignancies. Chemotherapy resistance in ovarian cancer cells has become a fundamental cause of poor clinical treatment and increased mortality. Therefore, looking for mechanisms related to drug resistance in ovarian cancer platinum drugs is crucial for improving the efficacy of chemotherapy in ovarian cancer. The pathophysiology of nuclear stem cell factor (Nucleostemin) mainly involves cell proliferation and apoptosis. Nucleostemin messenger RNA and Nucleostemin protein were highly expressed in solid tumors of ovarian cancer and positively correlated with pathological grade. Therefore, in-depth study of the sensitivity and molecular mechanism of Nucleostemin and ovarian cancer chemotherapy is very crucial.